ClinicalTrials.gg
Active, not recruitingNCT05382299ASCENT-03Updated Apr 6, 2026

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

A Phase 3 interventional study of Sacituzumab Govitecan-hziy and Paclitaxel in Triple Negative Breast Cancer and PD-L1 Negative, sponsored by Gilead Sciences. Active, not recruiting at 363 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
623
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing sacituzumab govitecan in Triple Negative Breast Neoplasms — 11 open to participants now, 18 under way, 6 of them phase 3. sacituzumab govitecan · Triple Negative Breast Neoplasms.

Enrollment
4th of 21
623 · median 138
Started
2022
with 2 others
Phase 3
6 of 21
2 open now
Primary completion
2028-07
later than 12 of 17 live
Registered
10th of 21
by date
Lead sponsor
8 of 21
Gilead Sciences

Among the 21 studies testing sacituzumab govitecan in Triple Negative Breast Neoplasms, this one is the 4th largest by enrollment, is one of 3 that started in 2022, is one of 6 in phase 3, reaches primary completion later than 12 of the 17 other live ones, and was the 10th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

11 of the 21 studies testing sacituzumab govitecan in Triple Negative Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About sacituzumab govitecan

sacituzumab govitecan: first FDA approval 2020 (TRODELVY), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing sacituzumab govitecan in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.

03

Conditions studied

  • Triple Negative Breast Cancer
  • PD-L1 Negative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Individuals, regardless of race and ethnic group, with previously untreated locally advanced, inoperable or triple-negative breast cancer (TNBC)

    • Individuals whose tumors are programmed cell death ligand 1 () negative at screening or individuals whose tumors are PD-L1 positive at screening if they have received an anti-PD-(L)1 inhibitor in the (neo) setting or if they cannot be treated with a checkpoint inhibitor due to a comorbidity
    • Centrally confirmed TNBC and PD-L1 status on fresh or
    • Individuals must have completed treatment for Stage I-III breast cancer, if indicated, and ≥ 6 months must have elapsed (with the exception of endocrine therapy) between completion of treatment with curative intent and first documented local or distant disease recurrence
    • Individuals presenting with de novo metastatic TNBC are eligible
  • based on computed tomography (CT) or magnetic resonance imaging (MRI) in accordance with per (RECIST) Version 1.1. as evaluated locally
  • (ECOG) performance status of 0 or 1
  • Demonstrates adequate organ function
  • Male individuals and female individuals of who engage in heterosexual intercourse must agree to use protocol-specified method(s) of
  • Individuals with (HIV) must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease

Key Exclusion Criteria:

  • Positive serum pregnancy test or women who are lactating
  • Received systemic anticancer treatment within the previous 6 months or radiation therapy within 2 weeks prior to enrollment
  • Have not recovered from adverse events (AEs) due to a previously administered agent at the time study entry
  • May not be participating in a study with an agent or investigational device within 4 weeks prior to randomization. Individuals participating in observational studies are eligible
  • Previously received topoisomerase 1 inhibitors or antibody drug conjugates containing a topoisomerase inhibitor
  • Active second
  • Active serious infection requiring antibiotics
  • Positive for HIV-1 or 2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease
  • Active virus (HBV) or virus (HCV) infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
623 participants (actual)

Study arms

  • Experimental
    Sacituzumab Govitecan-hziy (SG)

    Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle.

    Drug: Sacituzumab Govitecan-hziy

  • Active comparator
    Treatment of Physician's Choice (TPC)

    Participants will receive TPC determined prior to randomization from 1 of the 3 allowed regimens: * Paclitaxel 90 mg/m\^2 on Days 1, 8, and 15 of a 28-day cycle * Nab-paclitaxel 100 mg/m\^2 on Days 1, 8, and 15 of a 28-day cycle * Gemcitabine 1000 mg/m\^2 + carboplatin area under the curve (AUC) 2 on Days 1 and 8 of a 21-day cycle

    Drug: Paclitaxel · Drug: nab-Paclitaxel · Drug: Gemcitabine · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    PFS is defined as the time from the date of randomization until the date of objective progressive disease (PD), or death (whichever comes first).

    Time frame: Randomization up to approximately 57 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from the date of randomization until death due to any cause.

    Time frame: Randomization up to approximately 57 months

  2. Objective Response Rate (ORR) as Assessed by BICR per RECIST Version 1.1

    ORR is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) that is confirmed at least 4 weeks after initial documentation of response.

    Time frame: Randomization up to approximately 57 months

  3. Duration of Response (DOR) as Assessed by BICR per RECIST Version 1.1

    DOR is defined as the time from the first documentation of CR or PR to the earlier of the first documentation of definitive PD or death from any cause (whichever comes first).

    Time frame: Randomization up to approximately 57 months

  4. Time to Response (TTR) as Assessed by BICR per RECIST Version 1.1

    TTR is defined as the time from the date of randomization until the first documentation of CR or PR.

    Time frame: Randomization up to approximately 57 months

  5. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Time frame: First dose date up to approximately 57 months plus 30 days

  6. Percentage of Participants Experiencing Clinical Laboratory Abnormalities

    Time frame: First dose date up to approximately 57 months plus 30 days

  7. Change from Baseline in the Physical Functioning Domain as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core Questionnaire, Version 3.0 (EORTC QLQ-C30).

    The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients, it is composed of 30 questions (items) to assess 15 scales; 1 global health status/quality of life (QOL), 5 functional scales (physical, role, cognitive, emotional, and social), and 9 symptom/item scales(fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of function, a high score for the global health status/QOL represents a high QOL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.

    Time frame: Randomization up to approximately 57 months

  8. Time to Deterioration (TTD) of Fatigue Scale of the EORTC QLQ-C30

    TTD is defined as the time between the date of randomization and the date of assessment at which a patient experienced a deterioration (≥ 10 points deterioration from baseline in the fatigue scale) or death.

    Time frame: Randomization up to approximately 57 months

07

Study locations

363 sites
  • Arizona Oncology Associates, PC-Hope,1845 W Orange Grove Rd
    Tucson, Arizona 85704, United States
  • Arizona Oncology Associates, PC-Hope,2070 W. Rudasill Rd.
    Tucson, Arizona 85704, United States
  • Arizona Oncology Associates, PC-Hope
    Tucson, Arizona 85711, United States
  • Arizona Oncology Associates, PC-Hope,1620 West St. Mary's Road
    Tucson, Arizona 85745, United States
  • University of California Los Angeles - Jonsson Comprehensive Cancer Center,201 S. Buena Vista Street, Suite 200
    Burbank, California 91505, United States
  • University of California San Diego Moores Cancer
    La Jolla, California 92093, United States
  • University of California Los Angeles - Jonsson Comprehensive Cancer Center,24302 Paseo de Valencia, Suite 200
    Laguna Hills, California 91505, United States
  • University of California Los Angeles - Jonsson Comprehensive Cancer Center,892 Aerovista Place, Suite 240
    San Luis Obispo, California 93401, United States
  • University of California Los Angeles - Jonsson Comprehensive Cancer Center,2020 Santa Monica Blvd, Suite 600
    Santa Monica, California 90404, United States
  • University of California Los Angeles - Jonsson Comprehensive Cancer Center,2336 Santa Monica, Suites 302 and 304
    Santa Monica, California 90404, United States
  • University of California Los Angeles - Jonsson Comprehensive Cancer Center
    Santa Monica, California 90404, United States
  • Torrance Memorial Physician Network - Cancer Care
    Torrance, California 90505, United States
  • University of California Los Angeles - Jonsson Comprehensive Cancer Center,1250 La Venta Dr, Suite 100
    Westlake Village, California 91361, United States
  • Rocky Mountain Cancer Centers,1700 South Potomac Street
    Aurora, Colorado 80012, United States
  • Rocky Mountain Cancer Centers
    Boulder, Colorado 80303, United States
  • Rocky Mountain Cancer Centers,2312 N. Nevada Avenue
    Colorado Springs, Colorado 80907, United States
  • Rocky Mountain Cancer Centers,6031 E. Woodman Rd.
    Colorado Springs, Colorado 80923, United States
  • Rocky Mountain Cancer Centers,4700 E. Hale Parkway
    Denver, Colorado 80220, United States
  • Rocky Mountain Cancer Centers,11750 West 2nd Place
    Lakewood, Colorado 80228, United States
  • Rocky Mountain Cancer Centers,22 West Dry Creek Circle
    Littleton, Colorado 80120, United States
  • Rocky Mountain Cancer Centers,10107 Ridge Gate Parkway
    Lone Tree, Colorado 80124, United States
  • Rocky Mountain Cancer Centers,2030 Mountain View Ave Ste 210
    Longmont, Colorado 80124, United States
  • Rocky Mountain Cancer Centers,3676 Parker Blvd
    Pueblo, Colorado 81008, United States
  • Rocky Mountain Cancer Centers,525 W. 15th Street
    Pueblo, Colorado 81008, United States
  • Rocky Mountain Cancer Centers,8820 Huron Street
    Thornton, Colorado 80260, United States
  • AdventHealth Medical Group
    Altamonte Springs, Florida 32701, United States
  • Florida Cancer Specialists - North Region Research Office,750 Orienta Ave
    Altamonte Springs, Florida 32701, United States
  • Florida Cancer Specialists,9776 Bonita Beach Road Southeast Suite 201 A
    Bonita Springs, Florida 34135, United States
  • Florida Cancer Specialists,3630 Manatee Avenue West
    Bradenton, Florida 34205, United States
  • Florida Cancer Specialists,5985 Silver Falls Run
    Bradenton, Florida 34211, United States
  • Florida Cancer Specialists - North Region Research Office,403 S. Kings Ave.
    Brandon, Florida 33511, United States
  • Florida Cancer Specialists,1030 Commerce Creek Blvd
    Cape Coral, Florida 33909, United States
  • Florida Cancer Specialists - North Region Research Office,3280 McMullen Booth Road
    Clearwater, Florida 33761, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Florida Cancer Specialists,8981 Colonial Center Drive
    Fort Myers, Florida 33905, United States
  • Florida Cancer Specialists,8260 Gladiolus Dr
    Fort Myers, Florida 33908, United States
  • Florida Cancer Specialists - North Region Research Office,6420 W. Newberry Road
    Gainesville, Florida 32605, United States
  • Florida Cancer Specialists - North Region Research Office,100 Highland Avenue
    Largo, Florida 33770, United States
  • Florida Cancer Specialists - North Region Research Office,521 North Lecanto Highway
    Lecanto, Florida 34461, United States
  • Florida Cancer Specialists,1100 Goodlette Road
    Naples, Florida 34102, United States
  • Florida Cancer Specialists,681 4th Avenue North
    Naples, Florida 34102, United States
  • Florida Cancer Specialists - North Region Research Office,4945 SW 49th Place
    Ocala, Florida 34474, United States
  • Florida Cancer Specialists - North Region Research Office,2824 Enterprise Rd
    Orange City, Florida 32763, United States
  • AdventHealth Medical Group,2501 North Orange Ave
    Orlando, Florida 32804, United States
  • Florida Cancer Specialists - North Region Research Office,70 W. Gore Street
    Orlando, Florida 32806, United States
  • Florida Cancer Specialists,22395 Edgewater Drive
    Port Charlotte, Florida 33980, United States
  • Florida Cancer Specialists,600 North Cattlemen Road
    Sarasota, Florida 34232, United States
  • Florida Cancer Specialists,1970 Golf Street
    Sarasota, Florida 34236, United States
  • Florida Cancer Specialists - North Region Research Office,7154 Medical Center Drive
    Spring Hill, Florida 34608, United States
  • Florida Cancer Specialists - North Region Research Office,1201 Fifth Avenue North
    St. Petersburg, Florida 33705, United States
  • Florida Cancer Specialists - North Region Research Office
    St. Petersburg, Florida 33705, United States
  • Florida Cancer Specialists - North Region Research Office,3402 West Dr. Martin Luther King Jr. Boulevard
    Tampa, Florida 33607, United States
  • Florida Cancer Specialists - North Region Research Office,4100 Waterman Way
    Tavares, Florida 32778, United States
  • Florida Cancer Specialists - North Region Research Office,1400 US Highway 441 N
    The Villages, Florida 32159, United States
  • Florida Cancer Specialists - North Region Research Office,9320 State Road 54
    Trinity, Florida 34655, United States
  • Florida Cancer Specialists,901 South Tamiami Trail
    Venice, Florida 34285, United States
  • Florida Cancer Specialists,836 Sunset Lake Blvd
    Venice, Florida 34292, United States
  • Florida Cancer Specialists - North Region Research Office,460 N Orlando Ave
    Winter Park, Florida 32789, United States
  • Northside Hospital,125 King Avenue
    Athens, Georgia 30606, United States
  • Northside Hospital,5670 Peachtree Dunwoody Rd.
    Atlanta, Georgia 30342, United States
  • Northside Hospital
    Atlanta, Georgia 30342, United States
  • Northside Hospital,308 Deep South Farm Rd, Suite 200
    Blairsville, Georgia 30512, United States
  • Northside Hospital,228 Riverstone Dr.
    Canton, Georgia 30114, United States
  • Northwest Georgia Oncology Northwest Georgia Oncology Centers, PCCenters, PC,157 Clinic Avenue
    Carrollton, Georgia 30117, United States
  • Northwest Georgia Oncology Northwest Georgia Oncology Centers, PCCenters, PC,100 Market Place Blvd
    Cartersville, Georgia 30121, United States
  • Northside Hospital,1505 Northside Blvd, Suite 4600
    Cumming, Georgia 30041, United States
  • Northside Hospital,3855 Pleasant Hill Rd., Suite 480
    Duluth, Georgia 30096, United States
  • Northside Hospital,308 Coliseum Dr.
    Macon, Georgia 31217, United States
  • Northwest Georgia Oncology Northwest Georgia Oncology Centers, PCCenters, PC
    Marietta, Georgia 30060, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
    Chicago, Illinois 60611, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University,1 Kish Hospital Drive
    DeKalb, Illinois 60115, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University,10 Health Services Drive
    DeKalb, Illinois 60115, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University,300 Randall Road
    Geneva, Illinois 60134, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University,304 Randall Road
    Geneva, Illinois 60134, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University,1000 N. Westmoreland Road
    Lake Forest, Illinois 60045, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University,4405 Weaver Parkway
    Warrenville, Illinois 25731, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University,4455 Weaver Parkway
    Warrenville, Illinois 60555, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University,25 N Winfield Road
    Winfield, Illinois 60190, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Norton Cancer Institute - Saint Matthews,234 E. Gray Strret
    Louisville, Kentucky 40202, United States
  • Norton Cancer Institute - Saint Matthews,676 S. Floyd Street
    Louisville, Kentucky 40202, United States
  • Norton Cancer Institute - Saint Matthews
    Louisville, Kentucky 40207, United States
  • Norton Cancer Institute - Saint Matthews,4955 Norton Healthcare Blvd
    Louisville, Kentucky 40241, United States
  • Cancer Institute Ascension Saint Agnes
    Baltimore, Maryland 21229, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • The West Clinic, PLLC dba West Cancer Center,7668 Airways Blvd
    Southaven, Mississippi 38671, United States
  • New York Cancer & Blood Specialists - Port Jeffers,72 East Main St.
    Babylon, New York 11702, United States
  • New York Cancer & Blood Specialists - Port Jeffers,1 Delaware Dr.
    New Hyde Park, New York 11042, United States
  • New York Cancer & Blood Specialists - Port Jeffers,365 East Main St.
    Patchogue, New York 11772, United States
  • New York Cancer & Blood Specialists - Port Jeffers,1500 Rte, 112, Building 4
    Port Jefferson, New York 11776, United States
  • New York Cancer & Blood Specialists - Port Jeffers,49 Rte. 347, Newconset Hwy
    Port Jefferson Station, New York 11776, United States
  • New York Cancer & Blood Specialists - Port Jeffers
    Port Jefferson Station, New York 11776, United States
  • New York Cancer & Blood Specialists - Port Jeffers,750 Old County Rd. Suite 4
    Riverhead, New York 11901, United States
  • New York Cancer & Blood Specialists - Port Jeffers,12 East 86th St, Suite 4
    The Bronx, New York 10028, United States
  • New York Cancer & Blood Specialists - Port Jeffers,2330 Eastchester Road, Suite 360
    The Bronx, New York 10469, United States
  • Novant Health Cancer Institute - Forsyth,125 Queens Road, Suite 650
    Charlotte, North Carolina 28204, United States
  • Novant Health Cancer Institute - Forsyth,2131 S. 17th Street
    Wilmington, North Carolina 28401, United States
  • Novant Health Cancer Institute - Forsyth
    Winston-Salem, North Carolina 27103, United States
  • Magee-Womens Hospital of UPMC,2500 West 12th Street
    Erie, Pennsylvania 16505, United States

Showing the first 100 of 363 sites across 30 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Cortes J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, Tokunaga E, Brufsky A, Park YH, Xu B, Hegg R, Oliveira M, Fabi A, Vaksman N, Valdez T, Zhang X, Lai C, Tolaney SM; ASCENT-03 Clinical Trial Investigators. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. N Engl J Med. 2025 Nov 13;393(19):1912-1925. doi: 10.1056/NEJMoa2511734. Epub 2025 Oct 19. PubMed 41124233 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jul 2028, 72 months after the start.

Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 72 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2022
First posted
May 19, 2022
StartActual
Jul 20, 2022
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05382299
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
May 19, 2022
Start date
Jul 20, 2022
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Apr 6, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab govitecan

Start the discussion